{"id":"W2558690325","doi":"10.1093/neuonc/now212.068","title":"ATIM-03. ACT IV: AN INTERNATIONAL, DOUBLE-BLIND, PHASE 3 TRIAL OF RINDOPEPIMUT IN NEWLY DIAGNOSED, EGFRvIII-EXPRESSING GLIOBLASTOMA","year":2016,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Interim analysis; Temozolomide; Hazard ratio; Internal medicine; Oncology; Cohort; Clinical endpoint; Confidence interval; Randomized controlled trial; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002803198,0.0002667156,0.0007067933,0.000483822,0.00004737865,0.00002264778,0.000271959,0.0002361002,0.0004545469],"category_scores_gemma":[0.0003980661,0.00018791,0.0001675657,0.0002616417,0.0001505867,0.0003167443,0.000116414,0.0002106948,0.00008462609],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003206228,"about_ca_system_score_gemma":0.0003126173,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000121506,"about_ca_topic_score_gemma":0.000279217,"domain_scores_codex":[0.9977458,0.0002189667,0.0007189716,0.0005547525,0.000368931,0.0003925851],"domain_scores_gemma":[0.9977931,0.0009129362,0.0003612917,0.0005224677,0.0001557512,0.0002544238],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.3120846,0.01629745,0.03064968,0.0000242116,0.0001875581,0.003155539,0.0005117093,0.00002611456,0.4480344,0.0003229337,0.001346481,0.1873593],"study_design_scores_gemma":[0.7594054,0.01687271,0.003550747,0.0001664809,0.000163191,0.0001505684,0.00007384422,0.0001004655,0.1700915,0.00005428134,0.0491575,0.000213316],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9901573,0.00005715534,0.00001896413,0.003719115,0.001243892,0.001314918,0.00002805029,0.00005415272,0.003406425],"genre_scores_gemma":[0.9979897,0.0002254742,0.0002498596,0.0005048159,0.0006162903,0.0003215739,0.00002442413,0.00004312606,0.00002479545],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4473207,"threshold_uncertainty_score":0.7662747,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05272591588098204,"score_gpt":0.3763128567312981,"score_spread":0.323586940850316,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}